SIRT Versus cTACE for Unresectable HCC (CHANCE2506) — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

SIRT Versus cTACE for Unresectable HCC (CHANCE2506) — Stella

Home/Unresectable Hepatocellular Carcinoma/

View on ClinicalTrials.gov

Recruiting

Back to Unresectable Hepatocellular Carcinoma trials

Not a traditional drug trial — this study doesn't follow the standard phase structure.

Trial locations(1 site)

China

Zhongda Hospital, Southeast University, Nanjing, Jiangsu

Key details

Sponsor

Zhongda Hospital

Enrollment target

~108 participants

Started

April 2025

Primary completion

December 2026

Age range

18 Years and older

Last updated April 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.